Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049768 | 0.93 | CYP2D6 (0.45) | CYP2D6CYP2C9TSHRCYP3A4HIF1A | |
| SCHEMBL3056109 | 0.89 | HIF1A (0.42) | CYP2D6CYP2C9TSHRCYP3A4HIF1A | |
| SCHEMBL3063031 | 0.86 | CYP3A4 (0.44) | CYP2D6CYP2C9TSHRCYP3A4HIF1A | |
| SCHEMBL3042694 | 0.85 | CYP2D6 (0.45) | CYP2D6CYP2C9TSHRCYP3A4HIF1A | |
| SCHEMBL3059843 | 0.82 | BDKRB1 (0.39) | GFER | |
| SCHEMBL3052564 | 0.82 | OPRD1 (0.38) | TDP1 | |
| SCHEMBL3043136 | 0.82 | OPRD1 (0.35) | CYP2D6CYP2C9TSHRCYP3A4HIF1A | |
| SCHEMBL2876086 | 0.81 | CYP2D6 (0.44) | CYP2D6CYP2C9TSHRCYP3A4HIF1A | |
| SCHEMBL3056130 | 0.79 | BDKRB1 (0.51) | CYP2D6TSHRALDH1A1MAPK1 | |
| SCHEMBL3061729 | 0.79 | BDKRB1 (0.51) | TSHRALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | claimed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222324-A1 | Substituted Indole Compounds | BDKRB1, BDKRB2, EDNRB | CYP2D6 585/4885CYP2C9 499/4885TSHR 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.